compounded semaglutide. FDA Warns on Certain Forms of Semaglutide Semaglutide for weight loss |

This extended-release formulation of a GLP-1 receptor agonist aims to increase patients' convenience without compromising efficacy in treating obesity and type 2 diabetes

When we eat these comfort foods, our brain releases dopamine, creating a powerful, addictive cycle

Over an entire vial, the cumulative dead space can mean your last dose comes up slightly short

Many GLP-1 users need the higher end of supplementation

doi: 10.1152/ajpregu.00679.2005

The US Food and Drugs Administration's approval and widespread availability remain years away, but the drug's potential to revolutionise obesity treatment is evident, the study researchers say. Researchers are calling for additional studies, including head-to-head comparisons of GLP-1 drugs, to refine understanding of their efficacy and safety profiles